DIAL Health Supplement

项目摘要 卡路里限制(CR)的定义是吃营养充足的饮食，低于能量需求。Cr 已经被研究了近100年，并被发现延长了许多人的寿命和健康时间 物种。此外，当在年轻人和中年人身上进行测试时，适度的CR可以延长健康寿命并减缓 生物老化。然而，人们发现对CR的依从性随着时间的推移而下降，这让人对 这种方法的长期可行性。一种可能的CR替代方案，它可能具有更好的遵从性和 可接受性是指限时进食(Tre)，指的是一个人在8到10小时内吃完食物 天。Tre延长了啮齿动物的寿命，并且基于最近的人体试验，tre改善了疾病风险。 衰老的因素和生物标志物。此外，即使在减肥没有效果的情况下，tre的许多好处也是可以实现的。 发生。尽管CR和TRE的几个健康益处已经被记录在案，但这些 对癌症风险的干预，即tre，目前尚不清楚。因此，拟议的行政补编将 旨在解决与限时进食(Tre)和CR相关的未回答问题的支持分析 和癌症风险。该附录将支持奖项U01 AG073204(Dial Health，A规划项目试点 测试和优化饮食方法以延缓衰老并设计长期试验)和U01 AG073240(Hallo- P，健康老龄化和晚年结果规划)，以收集与癌症相关的终点，包括癌症病史 筛查，扩大的炎性生物标记物评估，以及肠道微生物组。两个家长奖 正在进行临床试验，测试CR和Tre对老化生物标志物的影响。具体来说，在表盘上 健康研究，该研究正在宾宁顿生物医学(洛杉矶巴吞鲁日)和宾夕法尼亚大学进行 阿拉巴马州伯明翰(亚利桑那州伯明翰)，将从90名成年参与者那里收集数据 在为期6个月的随机对照试验中。在Hallo-P研究期间，该研究正在维克森林进行 大学健康科学(温斯顿-塞勒姆，北卡罗来纳州)，120名老年人将参加为期9个月的随机 对照试验。

Project Summary Calorie restriction (CR) is defined as eating a nutritionally adequate diet that is below energy requirements. CR has been studied for almost 100 years and has been found to extend the lifespan and healthspan of numerous species. Further, when tested in young and middle-aged humans, modest CR improves healthspan and slows biological aging. However, adherence to CR has been found to decrease over time, calling into question the long-term viability of this approach. A possible alternative to CR that may have better adherence and acceptability is time-restricted eating (TRE), which involves eating one's food in an 8 to 10-hour period of the day. TRE extends the lifespan of rodents, and based on recent human trials, TRE improved disease risk factors and biomarkers of aging. Further, many benefits of TRE were achieved even when weight loss did not occur. Although several health benefits of CR and TRE have been documented, the effect of these interventions, namely TRE, on cancer risk is unclear. Thus, the proposed administrative supplement will support analyses aimed at addressing unanswered questions related to time-restricted eating (TRE) and CR and cancer risk. The supplement will support awards U01 AG073204 (DiAL Health, A planning project to pilot test and optimize dietary approaches to slow aging and design a long-term trial) and U01 AG073240 (HALLO- P, Health Aging & Later-Life Outcomes Planning) to collect cancer-related endpoints, including cancer history and screening, an expanded inflammatory biomarker assessment, and gut microbiome. The two parent awards are clinical trials that are testing the effects of CR and TRE on aging biomarkers. Specifically, in the DiAL Health study, which is being conducted at Pennington Biomedical (Baton Rouge, LA) and the University of Alabama at Birmingham (Birmingham, AL), data will be collected from 90 adult individuals who are participating in a 6-month randomized controlled trial. During the HALLO-P study, which is being conducted at Wake Forest University Health Sciences (Winston-Salem, NC), 120 older adults will be enrolled in a 9-month randomized controlled trial.